Observational studyFuture oncology (London, England)2026
Real-world data on patients with HR+, HER2- early breast cancer prescribed with abemaciclib adjuvant therapy for 2 years in Japan.
Yukinori Ozaki et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.